VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF CULMERCICLIB CAPSULE “CDK2/4/6 INHIBITOR” FOR FIRST-LINE TREATMENT OF BREAST CANCER APPROVED FOR MARKETING

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT